Shelley Zieroth
@shelleyzieroth.bsky.social
Heart Function Cardiologist, ❤️ 🇨🇦 Professor. Past Pres Federation of Medical Women of 🇨🇦 + Canadian HF Society. Clinical trialist. Everything Cardio-Kidney-Metabolic. #cardiosky #medsky
Reposted by Shelley Zieroth
#Finerenone reduced the risk of CV death and total worsening HF events, and was well-tolerated, independent of glycaemic status in HFmrEF/HFpEF
@escardio.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social @docbhardwaj.bsky.social
onlinelibrary.wiley.com/doi/full/10....
@escardio.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social @docbhardwaj.bsky.social
onlinelibrary.wiley.com/doi/full/10....
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, r...
onlinelibrary.wiley.com
April 13, 2025 at 4:34 PM
#Finerenone reduced the risk of CV death and total worsening HF events, and was well-tolerated, independent of glycaemic status in HFmrEF/HFpEF
@escardio.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social @docbhardwaj.bsky.social
onlinelibrary.wiley.com/doi/full/10....
@escardio.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social @docbhardwaj.bsky.social
onlinelibrary.wiley.com/doi/full/10....